Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension

Condition(s) studied

Investigational drug(s) / intervention(s)

Right heart catheterization: RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).

Study summary

Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.

Eligibility

Primary outcome measure(s)

• Accuracy of diagnosis by artificial intelligence-assisted algorithm — Baseline
  The investigators will calculate the area under the receiver operating characteristic curve of diagnosis by artificial intelligence-assisted algorithm and compare this index between artificial intelligence-assisted algorithm and RHC.

Trial sites (1)

More Chinese Pulmonary Vascular Disease Research Group trials in China

Other trials for the same condition